Psychedelic Business News Spotlight: April 2, 2021
Business
This week in psychedelic business news: cannabis dives in, ketamine delivery, and psilocybin for autism anxiety.
New breakthroughs in treatment using psychedelics.
Mydecine Innovations Group, a Denver, Colorado-based psychedelics research company, is taking an important first step in obtaining regulatory approval in the United States and Canada to develop psychedelic therapies and hold clinical trials with them. The company announced this week that it will unveil four novel drug candidates derived from natural psychedelics at Pre-Investigational New Drug meetings with the U.S. Food and Drug Administration (FDA) and Health Canada.
“Our first four novel drug candidates deliver on our long-term strategic road map for drug development with regular milestones that iteratively add value over time. By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates,” Joshua Bartch, Co-Founder and CEO, Mydecine Innovations Group, in a statement.
The candidates are derived from natural psychedelics, such as psilocybin, the psychoactive chemical in magic mushrooms. By altering the molecules, Mydecine is able to obtain a patent to market the compound.
The four novel drug candidates include:
“These candidates add layers of safety and dose-ability for the use of psychedelic compounds in medical research and eventually medical practice,” said Chief Science Office and Co-Founder of Mydecine Rob Roscow. “We want to create attractive features for the research community by providing compounds that can enhance therapy, reduce anxiety, and maximize delivery mechanisms.”
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.